Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Eli Lilly & Co (LLY)
NYSE:LLY
Eli Lilly & Co (LLY) Stock Price & Analysis
8,448 Followers
LLY Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$364.30 - $800.78
Previous Close$750.77
Volume1.72M
Average Volume (3M)3.07M
Market Cap
$709.22B
Enterprise Value$736.20B
Total Cash (Recent Filing)$2.93B
Total Debt (Recent Filing)$25.23B
Price to Earnings (P/E)129.4
Beta0.51
Next Earnings
Apr 30, 2024EPS Estimate
$2.47Last Dividend Ex-Date
Feb 14, 2024Dividend Yield0.63%
Share Statistics
EPS (TTM)5.68
Shares Outstanding950,164,452
10 Day Avg. Volume2,236,505
30 Day Avg. Volume3,074,034
Standard Deviation0.08
R-Squared0.05
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)-660.39
Price to Sales (P/S)20.91
Price to Cash Flow (P/CF)-568.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue21.57
Enterprise Value/Gross Profit27.22
Enterprise Value/Ebitda92.51
Forecast
1Y Price Target
$845.60Price Target Upside13.36% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering19
Eli Lilly & Co News
Bulls Say, Bears Say
Bulls Say
Clinical TrialsAnticipated compelling tirzepatide Phase 3 sleep apnea results could be a near-term positive catalyst.
Market ExpansionPositive data in one neurodegenerative condition will likely drive increased interest in the role of GLP-1 in others, most notably Alzheimer’s.
Product SalesZepbound and Mounjaro are anticipated to exceed sales expectations by a significant margin, potentially impacting the company's overall performance positively.
Bears Say
Drug Approval DelaysA regulatory hurdle for donanemab with an Advisory Committee indicates a delay in the expected regulatory decision.
Product Supply ConstraintsMounjaro and Zepbound TRx trends have recently declined due to supply constraints.
Regulatory ChallengesLegislative proposals for PBM rebate elimination could remove an important competitive barrier for LLY’s competitors.
---
Ownership Overview
11.10% Insiders
24.64% Mutual Funds
26.32% Other Institutional Investors
37.94% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
LLY FAQ
What was Eli Lilly & Co’s price range in the past 12 months?
Eli Lilly & Co lowest stock price was $364.30 and its highest was $800.78 in the past 12 months.
What is Eli Lilly & Co’s market cap?
Currently, no data Available
When is Eli Lilly & Co’s upcoming earnings report date?
Eli Lilly & Co’s upcoming earnings report date is Apr 30, 2024 which is in 11 days.
How were Eli Lilly & Co’s earnings last quarter?
Eli Lilly & Co released its earnings results on Feb 06, 2024. The company reported $2.49 earnings per share for the quarter, beating the consensus estimate of $2.296 by $0.194.
Is Eli Lilly & Co overvalued?
According to Wall Street analysts Eli Lilly & Co’s price is currently Undervalued.
Does Eli Lilly & Co pay dividends?
Eli Lilly & Co pays a Quarterly dividend of $1.3 which represents an annual dividend yield of 0.63%. See more information on Eli Lilly & Co dividends here
What is Eli Lilly & Co’s EPS estimate?
Eli Lilly & Co’s EPS estimate is $2.47.
How many shares outstanding does Eli Lilly & Co have?
Eli Lilly & Co has 950,766,100 shares outstanding.
What happened to Eli Lilly & Co’s price movement after its last earnings report?
Eli Lilly & Co reported an EPS of $2.49 in its last earnings report, beating expectations of $2.296. Following the earnings report the stock price went down -0.165%.
Which hedge fund is a major shareholder of Eli Lilly & Co?
Among the largest hedge funds holding Eli Lilly & Co’s share is PRIMECAP Management Co. It holds Eli Lilly & Co’s shares valued at 13B.
---
Eli Lilly & Co Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$845.60 (13.36% Upside)
$845.60 (13.36% Upside)
Blogger Sentiment
Bullish
LLY Sentiment 79%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 467.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $465.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days <0.1%
Last 30 Days ▼ 2.2%
Last 30 Days ▼ 2.2%
News Sentiment
Bullish
Bullish news 69%
Bearish news 31%
Bearish news 31%
Technicals
SMA
Positive
20 days / 200 days
Momentum
103.31%
12-Months-Change
Fundamentals
Return on Equity
48.93%
Trailing 12-Months
Asset Growth
29.33%
Trailing 12-Months
Company Description
Eli Lilly & Co
Founded in 1876, Eli Lilly & Co. is a leading healthcare company that manufactures and sells pharmaceutical products worldwide. The company is headquartered in Indianapolis, Indiana.
---
LLY Company Deck
---
LLY Earnings Call
Q4 2024
0:00 / 0:00
---
LLY Revenue Breakdown
84.44% Net product revenue
15.56% Collaboration and other revenue
---
LLY Stock 12 Months Forecast
Average Price Target
$845.60
▲(13.36% Upside)
Technical Analysis
Best Analysts Covering LLY
1 Year
1 Year Success Rate
26/26 ratings generated profit
1 Year Average Return
+53.92%
reiterated a buy rating last month
Copying Terence Flynn's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +53.92% per trade.
---